Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01550367 · ClinicalTrials.gov registry record · Phase 1
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
A Phase 1 study, sponsored by Leonard Appleman.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01550367 is a Phase 1 study that has completed, run by Leonard Appleman. The registered enrollment target is 30 participants.
The verdict
NCT01550367, a Phase 1 study, has completed, sponsored by Leonard Appleman.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The main goal of the research study is to determine whether treating renal cell cancer patients with the study drug, hydroxychloroquine, along with IL-2, a standard treatment of kidney cancer that has spread to other parts of the body, can make the cancer easier to kill and eliminate. Another goal is to see how the study drug affects the body's immune cells which fight cancer cells.
Interventions
- DRUG IL-2
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-03 |
| Est. Completion | 2019-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01550367
The ClinicalTrials.gov registry entry for NCT01550367 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Leonard Appleman, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IL-2 is the first listed.
NCT01550367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01550367 about?
NCT01550367 is a clinical study titled "Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)". The main goal of the research study is to determine whether treating renal cell cancer patients with the study drug, hydroxychloroquine, along with IL-2, a standard treatment of kidney cancer that has spread to other parts of the body, can make the cancer easier to kill and eliminate. Another goal i...
What is the current status of trial NCT01550367?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-03. Estimated completion is 2019-02.
What interventions are being tested in trial NCT01550367?
The interventions under investigation include: IL-2 (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT01550367?
This trial is sponsored by Leonard Appleman, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.